These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34687287)

  • 1. Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes.
    van Haren F; van den Heuvel S; Ligtenberg M; Vissers K; Steegers M
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1577. PubMed ID: 34687287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
    Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
    Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
    Jin L; Zhang Y; Yang W
    Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
    Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
    J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
    Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
    Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
    Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
    Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
    Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
    Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
    Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
    Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
    Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
    Greenwald MK; Ruterbusch JJ; Beebe-Dimmer JL; Simon MS; Albrecht TL; Schwartz AG
    Cancer; 2019 Jan; 125(2):269-277. PubMed ID: 30387871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.
    Zhi WI; Baser RE; Kwon A; Chen C; Li SQ; Piulson L; Seluzicki C; Panageas KS; Harte SE; Mao JJ; Bao T
    Breast Cancer Res Treat; 2021 Apr; 186(3):761-768. PubMed ID: 33507480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
    Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
    Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison.
    Johnson K; Stoffel B; Schwitter M; Hayoz S; Rojas Mora A; Fischer Maranta A; El Saadany T; Hasler U; von Moos R; Patzen A; Mark M; Roberts G; Cathomas R
    Support Care Cancer; 2024 Jul; 32(8):554. PubMed ID: 39066890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
    Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
    BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale.
    Frigeni B; Piatti M; Lanzani F; Alberti P; Villa P; Zanna C; Ceracchi M; Ildebrando M; Cavaletti G
    J Peripher Nerv Syst; 2011 Sep; 16(3):228-36. PubMed ID: 22003937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy.
    Velasco R; Santos C; Soler G; Gil-Gil M; Pernas S; Galan M; Palmero R; Bruna J
    J Peripher Nerv Syst; 2016 Sep; 21(3):134-41. PubMed ID: 27282616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer.
    Verhoeff-Jahja R; Ter Kuile MM; Weijl NI; Oosterkamp R; Cloos M; Portielje JEA; Kroep JR; Hinnen C
    Support Care Cancer; 2022 Aug; 30(8):6947-6953. PubMed ID: 35543818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.